ArticleWorld journal of clinical cases2021
Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality.
Article in World journal of clinical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Benign course of hepatitis A and COVID-19 coinfection: A retrospective observational case series with comparative analysis.IDCases · 2026Article
- Article
- The Interplay of Chronic Hepatitis C and COVID-19: Implications for Prognosis and Treatment.Cureus · 2024Article
- Analysis of articles on hepatitis C by scientific mapping: 1989-2022.World journal of clinical cases · 2024Article
- Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.Hepatology forum · 2024Review
- Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate.Life (Basel, Switzerland) · 2023Article
- Review
- Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.Microbiology spectrum · 2023Article
- Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury.Viruses · 2023Review
- Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination.World journal of gastroenterology · 2023Review
- Outcomes of COVID-19 among patients with liver disease.World journal of gastroenterology · 2023Review
- COVID-19 and the liver: Are footprints still there?World journal of gastroenterology · 2023Review
- COVID-19 in patients with pre-existing chronic liver disease - predictors of outcomes.World journal of virology · 2023Review
- COVID-19: Has the Liver Been Spared?International journal of molecular sciences · 2023Review
- COVID-19 and the Liver: A Complex and Evolving Picture.Hepatic medicine : evidence and research · 2023Article
- Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.Medicina (Kaunas, Lithuania) · 2022Review
- Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective.World journal of virology · 2022Review
- Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.Journal of hepatology · 2022Article
- SARS-CoV-2 infection and liver involvement.Hepatology international · 2022Review
- Mortality Predictors in Severe SARS-CoV-2 Infection.Medicina (Kaunas, Lithuania) · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is little evidence about the association of pre-existing hepatitis C infection (HCV) with outcomes in patients with coronavirus disease 2019 (COVID-19).
aimTo assess the prevalence of history of HCV among patients with COVID-19 and to study the relationship of in-hospital mortality in relation with other predictors of poor outcomes in the presence or absence of COVID-19 induced acute liver injury.
methodsIn a retrospective single-center study design, 1193 patients with COVID-19 infection were studied. Patients were then classified into those with and without a history of HCV, 50 (4.1%) and 1157 (95.9%) respectively.
resultsMultivariate cox-regression models showed that age, HCV, D-Dimer, and ferritin were the only predictors of in-hospital mortality. Acute liver injury and fibrosis score (Fib-4 score) were not different between both groups. Multivariate cox-regression model for liver profile revealed that aspartate aminotransferase/ alanine aminotransferase ratio, Fib-4 score, and HCV were predictors of in-hospital mortality. After propensity score matching HCV was the only predictor of mortality in the multivariate cox-regression model. A model including HCV was found to add predictive value to clinical and laboratory parameters.
conclusionIn patients with COVID-19, history of HCV infection leads to an accentuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virulence, irrespective of baseline comorbidities, admission laboratory variables, or COVID-19-induced liver injury, which may be related to extrahepatic effects of HCV leading to enhanced ACE-2/TMPRSS mechanisms of SARS-CoV-2 viral entry, baseline cytokine-mediated pro-inflammation, and endothelial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.